Depression if untreated at an early stage may prove fatal often resulting in suicidal tendency in ailing patients. According to the statistics provided by World Health Organization (WHO), each year 800,000 people die due to suicide. It is important for physicians to perform accurate diagnosis and identify cormorbid symptoms to confirm treatment resistant depression in ailing patients.
This report contains market size and forecasts of Treatment Resistant Depression in Global, including the following market information:
Global Treatment Resistant Depression Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Treatment Resistant Depression market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Selective Serotonin Reuptake Inhibitors Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Treatment Resistant Depression include Bristol Myers Squibb Company, Eli Lilly & Company, Janssen Pharmaceutcials, Inc., Mylan Pharmaceutcials, Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., Valeant Pharmaceuticals International and Validus Pharmaceuticals LLC and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Treatment Resistant Depression companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Treatment Resistant Depression Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Treatment Resistant Depression Market Segment Percentages, by Type, 2021 (%)
Selective Serotonin Reuptake Inhibitors
Monoamine Oxidase Inhibitors
Tricyclic Antidepressant
Esketamine Nasal Spray
Global Treatment Resistant Depression Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Treatment Resistant Depression Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinic
Others
Global Treatment Resistant Depression Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Treatment Resistant Depression Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Treatment Resistant Depression revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Treatment Resistant Depression revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bristol Myers Squibb Company
Eli Lilly & Company
Janssen Pharmaceutcials, Inc.
Mylan Pharmaceutcials, Inc.
Novartis AG
Otsuka Pharmaceutical Co., Ltd.
Pfizer, Inc.
Valeant Pharmaceuticals International
Validus Pharmaceuticals LLC
Wyeth